当前位置: X-MOL 学术Microb. Biotechnol. › 论文详情
Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)
COVID-19: From pathogenesis models to the first drug trials.
Microbial Biotechnology ( IF 4.8 ) Pub Date : 2020-06-23 , DOI: 10.1111/1751-7915.13611
Harald Brüssow 1
Affiliation  

The number of people infected with SARS‐CoV‐2, and sadly dying from COVID‐19, has exploded, and so the amount of literature on the novel coronavirus and the disease it causes has increased proportionately. The case numbers in some countries are beyond the epidemic peak, but the uncertainty about a second wave keeps politicians and societies under pressure. Appropriate decision‐making and winning support from the population depends on precise scientific information rather than leaving the field to scaremongers of all proveniences. This mini‐review is an update of earlier reports (Brüssow, Microb Biotechnol 2020a;13:607; Brüssow, Microb Biotechnol 2020b; https://doi.org/10.1111/1751-7915.13592).

中文翻译:

COVID-19:从发病机制模型到首次药物试验。

感染 SARS-CoV-2 并不幸死于 COVID-19 的人数呈爆炸式增长,因此有关新型冠状病毒及其引起的疾病的文献数量也相应增加。一些国家的病例数已超过疫情高峰,但第二波疫情的不确定性让政界和社会面临压力。适当的决策和赢得民众的支持取决于精确的科学信息,而不是让这个领域留给各种来源的危言耸听者。本小型综述是对早期报告的更新(Brüssow,Microb Biotechnol 2020a;13:607;Brüssow,Microb Biotechnol 2020b;https://doi.org/10.1111/1751-7915.13592)。
更新日期:2020-06-23
down
wechat
bug